Moratorium In Xenotransplantation Urged

28 January 1998

Leading scientists have called for a moratorium on clinicalxenotransplantation "until ethical issues associated with the transfer of organs from animals to humans are resolved."

The call came just as the US National Institutes of Health began a two-day meeting last month, entitled Developing US Public Health Service Policy in Xenotransplantation, to propose tightening control over animal-to-human transplants. Fritz Bach, a researcher of xenotransplantation at Harvard University and a consultant to Novartis Pharma, joined six other public health experts and bioethicists in urging a moratorium.

The heightened interest in xenotransplantation stems from considerable advances in genetic engineering which makes it conceivable that the technology will become a reality.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight